AVM0703

DRUG3 trials

Sponsors

AVM Biotechnology Inc

Conditions

ARDSAcute LeukemiaBreast CancerCancerCovid19Desmoplastic Round Cell SarcomaEsophageal AndeocarcinomaGastric Cancer

Phase 1

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

RecruitingNCT04329728

AVM Biotechnology IncLymphoid Malignancies

Start: 2020-11-06End: 2028-12-01Target: 144Updated: 2026-04-15

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS

Not yet recruitingNCT04366115

AVM Biotechnology IncARDS, Covid19, Influenza, Human

Start: 2026-12-01End: 2032-03-01Target: 16Updated: 2025-10-02

Unknown Phase

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

AVM Biotechnology IncAcute Leukemia, Breast Cancer, Cancer +14

Updated: 2025-10-02

Related Papers

Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.

Journal of Clinical Oncology2024-06-011 citations

Very-High Dose Dexamethasone Mobilizes Endogenous Bi-Specific Gamma Delta+ NKT Cells

Blood2021-11-05